1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Asia Green Biotechnology Corp.

Asia Green Biotechnology Corp.

ASIA.CN
Asia Green Biotechnology Corp.CA flagCanadian Securities Exchange
0.02
CAD
- -
- -
543,706.00Market Cap
Asia Green Biotechnology Corp.
ASIA.CN
(Canadian Securities Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.03
-0.02
-0.02
- -
-0.01
-0.01
Basic EPS, GAAP
- -
-0.03
-0.02
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.01
- -
-0.02
-0.03
-0.03
-0.04
-0.04
Book Value per Share
0.01
0.04
0.01
- -
-0.01
-0.01
-0.02
Tangible Book Value per Share
36
24
28
34
36
36
36
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
-1
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1
- -
- -
- -
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
- -
- -
- -
- -
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
1
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
51.47%
91.85%
Free Cash Flow
- -
109.56%
-71.21%
Net Income, GAAP
- -
-16.74%
34.85%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Aurora Cannabis Inc. (ACB)
Blueberries Medical Corp. (BBRRF)
Biofrontera AG (B8FK.DE)
Mangalam Drugs & Organics Limited (MANGALAM.BO)
INDVR Brands Inc. (IDVR.CN)
Jushi Holdings Inc. (JUSH.CN)
Business
Asia Green Biotechnology Corp. operates as an early-stage international biotechnology firm, concentrating on the advancement, assessment, testing, deployment, and provision of products derived from its specialized organic hybridization processes, primarily across Asian territories. The enterprise centers its efforts on cultivating, nurturing, and harvesting novel and valuable varieties of hemp and associated plants in significant commercial quantities. Through strategic agreements with entities like Pathway Rx Inc. and Swysh Inc., the company has been involved in the clinical development and potential commercialization of cannabis sativa strains aimed at preventing and treating various infectious diseases, including COVID-19, and exploring cannabinoid-based topical treatments. Founded in 2017, the company, formerly known as Asia Cannabis Corp. before its renaming in April 2020, is headquartered in Calgary, Canada. In recent developments, the company terminated a previously announced letter of intent in August 2024 for an acquisition, citing regulatory and market challenges. Furthermore, a Management Cease Trade Order was issued in May 2024 by the Alberta Securities Commission due to delays in filing required financial documentation.